/ /

  • linkedin
  • Increase Font
  • Sharebar

    Promising results for keratitis treatment with use of CXL, riboflavin

    Small study supports what other researchers have found for combined, solo therapy


    Dr. El Habbak presented results from 10 eyes of 10 patients who were treated with riboflavin and UV CXL for refractory infectious keratitis. All patients had been treated with both topical and systemic antibiotics but had not responded to the treatments over 2 weeks. The antibiotics included fortified vancomycin (50 mg/ml) and ceftazidime (50 mg/ml) plus topical amphotericin B (0.1 mg/ml) if there was also a fungal infection. Systemic therapy included ciprofloxacin and linezolid as well as amphotericin B for fungal infections.

    The antimicrobials were stopped for 24 hours, and a corneal swab was performed to search for the bacterial or fungal infection source, Dr. El Habbak said.

    Patients also were assessed via slit lamp exams and photos, best-corrected visual acuity (BCVA), and ultrasound pachymetry of their corneal thickness.

    Patients were treated with UV CXL and 0.1% riboflavin drops used every 3 minutes for 30 minutes.

    After treatment, topical and systemic antibiotics were continued for 1 week. Follow-up visits were at 1 week, 1 month, and 3 months. All patients had their BCVA measured, a corneal swab performed, and slit lamp-colored corneal photos taken.

    “Progression of keratitis was stopped in all cases,” Dr. El Habbak said. “The mean BCVA improved from 0.9 logMAR pre-CXL to 0.1 logMAR 3 months after treatment.”

    Pain also improved in all cases. None of the 10 cases required emergency keratoplasty, the latter of which could lead to rejection or reinfection.

    The results support other published literature regarding the use of CXL and antibiotics combined or CXL as a solo treatment, Dr. El Habbak said.

    Although infectious keratitis must be managed with extreme caution, the use of CXL appears to be a promising adjuvant therapy, Dr. El Habbak concluded.


    Ashraf H. El Habbak, MD, PhD

    e: [email protected]

    This article was adapted from Dr. El Habbak’s presentation during Refractive Subspecialty Day at the 2017 meeting of the American Academy of Ophthalmology. Dr. El Habbak has no disclosures.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results